Timothy Rolph Sells 12,500 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) insider Timothy Rolph sold 12,500 shares of the business's stock in a transaction on Monday, July 7th. The shares were sold at an average price of $51.09, for a total transaction of $638,625.00. Following the transaction, the insider owned 167,124 shares in the company, valued at $8,538,365.16. The trade was a 6.96% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Timothy Rolph also recently made the following trade(s):

• On Wednesday, June 18th, Timothy Rolph sold 1,129 shares of Akero Therapeutics stock. The shares were sold at an average price of $54.84, for a total transaction of $61,914.36.
• On Tuesday, June 10th, Timothy Rolph sold 2,358 shares of Akero Therapeutics stock. The shares were sold at an average price of $54.00, for a total transaction of $127,332.00.
• On Thursday, June 5th, Timothy Rolph sold 12,500 shares of Akero Therapeutics stock. The shares were sold at an average price of $53.49, for a total transaction of $668,625.00.
• On Friday, June 6th, Timothy Rolph sold 25,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $55.04, for a total transaction of $1,376,000.00.
• On Tuesday, May 6th, Timothy Rolph sold 12,500 shares of Akero Therapeutics stock. The shares were sold at an average price of $43.43, for a total transaction of $542,875.00.
• On Thursday, April 24th, Timothy Rolph sold 6,250 shares of Akero Therapeutics stock. The shares were sold at an average price of $41.03, for a total transaction of $256,437.50.

Akero Therapeutics Stock Performance

Shares of NASDAQ:AKRO traded down $0.43 during midday trading on Friday, reaching $51.57. The company had a trading volume of 618,863 shares, compared to its average volume of 1,053,837. The company's 50 day moving average price is $49.45 and its 200 day moving average price is $43.34. The company has a current ratio of 16.80, a quick ratio of 16.80 and a debt-to-equity ratio of 0.03. The stock has a market cap of $4.11 billion, a P/E ratio of -26.45 and a beta of -0.15. Akero Therapeutics, Inc. has a 52-week low of $21.34 and a 52-week high of $58.40.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported $0.90 earnings per share for the quarter, topping analysts' consensus estimates of ($1.01) by $1.91. As a group, sell-side analysts anticipate that Akero Therapeutics, Inc. will post -3.99 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. Bank of America upped their target price on shares of Akero Therapeutics from $63.00 to $64.00 and gave the stock a "buy" rating in a research note on Tuesday, May 27th. Citigroup reduced their target price on shares of Akero Therapeutics from $80.00 to $78.00 and set a "buy" rating for the company in a research note on Tuesday, May 13th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Akero Therapeutics has an average rating of "Buy" and an average target price of $82.50.

Hedge Funds Weigh In On Akero Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in AKRO. Proficio Capital Partners LLC purchased a new position in shares of Akero Therapeutics in the 4th quarter worth about $320,000. Charles Schwab Investment Management Inc. lifted its holdings in Akero Therapeutics by 1.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 540,692 shares of the company's stock valued at $15,042,000 after purchasing an additional 8,096 shares during the last quarter. AlphaQuest LLC lifted its holdings in Akero Therapeutics by 32,588.0% during the fourth quarter. AlphaQuest LLC now owns 8,172 shares of the company's stock valued at $227,000 after purchasing an additional 8,147 shares during the last quarter. Great Lakes Advisors LLC purchased a new stake in Akero Therapeutics during the fourth quarter valued at about $5,380,000. Finally, Swiss National Bank lifted its holdings in Akero Therapeutics by 1.2% during the fourth quarter. Swiss National Bank now owns 95,600 shares of the company's stock valued at $2,660,000 after purchasing an additional 1,100 shares during the last quarter.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.